Cytokine Levels in Conversion Disorder

The aim of this study is whether the proinflammatory cytokine levels in patients with conversion disorder is increased or not changed in the acute phase and subacute - chronic periode, compared with controls.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Conversion Disorder Inflammation Mental Disorders Pathologic Processes Pathological Conditions, Signs and Symptoms Somatoform Disorders

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Trakya University Faculty of Medicine; Department of Psychiatry

Edirne, 22030, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Clinical diagnosis of Alzheimer's Disease

Exclusion criteria

Autoimmune disease
Neurological disease
Any organic disorder that could possibly affect proinflammatory cytokines
Pregnancy
Any drug usage within 2 weeks
Any active or passive immunization within 6 months
Any other DSM-IV axis I psychiatric disorder
Mental retardation
Developmental disorder of childhood

Treatment and study plan

conversion disorder

Other

Proinflammatory cytokine levels in conversion disorder

Sponsors and collaborators

Lead sponsor

Trakya University

Other

Registry information

Official study title

Proinflammatory Cytokine Levels in Patients With Conversion Disorder

Important dates

Study start: 2009
Primary completion: 2010
Study completion: 2010
First posted: Sep 3, 2009
Registry last updated: Oct 20, 2010

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed